Hoffmann-La Roche Limited (Roche Canada) today announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for EVRYSDI® (risdiplam), a pre-mRNA splicing modifier of survival of motor neuron 2 (SMN2) designed to treat SMA, indicated for the treatment of spinal muscular atrophy (SMA) in patients two months of age or older.1
Read MoreRoche Canada is pleased to announce the launch of the Roche Data Science Coalition, a group of like-minded public and private organizations committed to working with the global community to develop solutions to the challenges of the COVID-19 pandemic. The collaborators in the Coalition include: Alberta Machine Intelligence Institute (Amii), doc.ai, NVIDIA, Self Care Catalysts, ThinkData Works Inc and Vector Institute.
Read More